Tadalafil: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
PBAC (Australia), PHARMAC (New Zealand) and SMC (Scotland) recommended or restricted tadalafil, while AWMSG (Wales) and TLV (Sweden) did not recommend it.
On the same population the two systems disagree outright: PBAC (Australia) recorded recommended for “Pulmonary arterial hypertension (PAH)”, while AWMSG (Wales) recorded not recommended for “For the treatment of pulmonary arterial hypertension (PAH).”.
HAS (France) has been harder on tadalafil than on its own caseload: it refused 5 of 15 decisive submissions here (33%), against a base rate of 11% across everything it has assessed.
The file has been open for more than a decade: 22.8 years separate the first record, 9 May 2003 at SMC (Scotland), from the most recent, 23 Feb 2026 at PHARMAC (New Zealand).
SMC (Scotland) changed its position: recommended on 8 Jun 2009, restricted by 9 Jul 2012.
No assessment is on file from CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for tadalafil, 1 submission was never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 6 of 27 records date from 2023 or later.
5 distinct indication wordings are recorded for tadalafil by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 27 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess tadalafil, on 9 May 2003; PBAC (Australia) did not open a file until 2024 — an unusually long tail of 21.2 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 15 years in total.
4 of the 7 agencies here assessed tadalafil more than once, HAS (France) most often at 15 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for tadalafil.
The full ledger for tadalafil reads 14 recommended, 8 not recommended, 1 advice and 1 terminated, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PHARMAC (New Zealand) | 23 Feb 2026 | Perioperative use in cardiac surgery patients | PTAC advice: Cost Neutral | source |
| PBAC (Australia) | 2024 | Pulmonary arterial hypertension (PAH) | Recommended | source |
| HAS (France) | 5 Jul 2023 | Listing (Transparency Committee) | SMR insufficient · ASMR V | source |
| AWMSG (Wales) | 22 Mar 2013 | For the treatment of the signs and symptoms of benign prostatic hyperplasia in adult males. | not endorsed (non-submission) | source |
| NICE (England) | 23 Jan 2013 | NICE TA273 | terminated appraisal | source |
22 further decisions for tadalafil, across 5 agencies, are not shown here. They include the most recent record on file, 23 Feb 2026 from PHARMAC (New Zealand); its outcome is in the subscriber dataset. They link to 20 further source documents.
Related molecules
- sildenafil — same ATC class G04B — Urologicals
- mirabegron — same ATC class G04B — Urologicals
- apomorphine — same ATC class G04B — Urologicals
- solifenacin — same ATC class G04B — Urologicals
- vibegron — same ATC class G04B — Urologicals
- oxybutynin — same ATC class G04B — Urologicals
Coverage: 27 decisions for tadalafil from 7 agencies, 2003 to 2026. Data to 7 Sep 2026. ATC class G04B — Urologicals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.